论文部分内容阅读
目的观察利伐沙班预防晚期肺癌患者发生静脉血栓栓塞(venous thromboembolism,VTE)的疗效及安全性。方法选择VTE风险评估(Caprini模型)≥5分的20例晚期非小细胞肺癌患者为研究对象,在住院期间进行预防性利伐沙班治疗,分析治疗后VTE发生率、出血风险和各项观察指标与VTE发生率的关系。结果预防性利伐沙班治疗后的VTE发生率为1 0.0%(2/2 0),治疗前D-二聚体升高的患者VTE发生率明显高于D-二聚体正常的患者,差异有统计学意义(P<0.0 5),其余各项观察指标与VTE发生率比较,差异均无统计学意义(P>0.05),全组病例未出现与利伐沙班相关的不良反应。结论利伐沙班可在一定程度上减少晚期肺癌患者VTE的发生率,药物安全可靠。
Objective To observe the efficacy and safety of rivaroxaban in preventing venous thromboembolism (VTE) in patients with advanced lung cancer. Methods Twenty patients with advanced non-small cell lung cancer (NSCLC) with VTE risk assessment (Caprini model) ≥5 were enrolled in the study. Patients were treated with propofol shauban during hospitalization. The incidence of VTE, the risk of bleeding and various observations after treatment were analyzed The relationship between the index and the incidence of VTE. Results The incidence of VTE after preventive rivaroxaban treatment was 1 0.0% (2/2 0). The incidence of VTE in patients with elevated D-dimer before treatment was significantly higher than that in patients with normal D-dimer, (P <0.05). There was no significant difference between the other indexes and the incidence of VTE (P> 0.05). No adverse reactions were observed in all the patients with rivaroxaban. Conclusion Rivaroxaban can reduce the incidence of VTE in patients with advanced lung cancer to a certain extent, and the drug is safe and reliable.